Therefore, in the current study, we aimed to study (1) whether circulating GDF15 levels differ between Dutch South Asian and Dutch Europid patients with T2DM; (2) whether the GLP‐1R agonist liraglutide modifies plasma levels of GDF15 in either ethnicity; and (3) whether changes in GDF15 levels are related to the reduction in body weight after liraglutide treatment in either ethnicity. The gene discussed is GDF15; the disease is type 2 diabetes mellitus.